Table 2 Disease events and deaths prevented with the two vaccination strategies associated with cervical screening
HPV 16/18/31/33/45/52/58 related disease incidence cases and deaths | Years since start of vaccination programme | ||
|---|---|---|---|
25 | 50 | 100 | |
CIN1 cases- females | |||
 4vHPV vs screening (nb of events avoided) | 3125 | 11,579 | 31,382 |
 9vHPV vs screening (nb of events avoided) | 4278 | 16,146 | 44,084 |
 9vHPV vs 4vHPV (nb of events avoided) | 1153 | 4567 | 12,702 |
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%) | 10.4 | 27.1 | 49.8 |
CIN2 cases- females | |||
 4vHPV vs screening (nb of events avoided) | 3948 | 14,852 | 40,551 |
 9vHPV vs screening (nb of events avoided) | 5321 | 20,254 | 55,552 |
 9vHPV vs 4vHPV (nb of events avoided) | 1373 | 5401 | 15,000 |
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%) | 9.8 | 25.6 | 47.8 |
CIN3 cases- females | |||
 4vHPV vs screening (nb of events avoided) | 4232 | 18,227 | 54,031 |
 9vHPV vs screening (nb of events avoided) | 5224 | 22,789 | 67,893 |
 9vHPV vs 4vHPV (nb of events avoided) | 991 | 4562 | 13,862 |
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%) | 5.2 | 16.1 | 35.5 |
Cervical cancer cases- females | |||
 4vHPV vs screening (nb of events avoided) | 242 | 2316 | 10,414 |
 9vHPV vs screening (nb of events avoided) | 305 | 2961 | 13,394 |
 9vHPV vs 4vHPV (nb of events avoided) | 63 | 644 | 2979 |
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%) | 1.2 | 7.1 | 24.2 |
Cervical cancer deaths- females | |||
 4vHPV vs screening (nb of deaths avoided) | 16 | 399 | 2554 |
 9vHPV vs screening (nb of deaths avoided) | 20 | 512 | 3295 |
 9vHPV vs 4vHPV (nb of events avoided) | 4 | 113 | 741 |
 Cumulative incidence decrease, 9vHPV vs 4vHPV (%) | 0.3 | 4.1 | 19.7 |